Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633111 · ClinicalTrials.gov registry record
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
A clinical trial of B-Cell Non-Hodgkin Lymphoma and Aggressive, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 501
- Enrollment target
- 12
- Study locations
NCT02633111 is a study of B-Cell Non-Hodgkin Lymphoma and Aggressive that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 501 participants, above the 109-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (360% higher). The trial reports 12 study locations across 6 states.
The verdict
NCT02633111, a study of B-Cell Non-Hodgkin Lymphoma and Aggressive, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 501 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can potentially replace CT scans after completion of chemotherapy in the future.
Conditions Studied
Interventions
- DEVICE PET/CT
- OTHER collected at pre-treatment tumor biopsy
- OTHER Peripheral blood tests
Study Locations (12)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Cancer Center - Harrison
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Florida
- University of Miami - Miami
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2015-10 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633111
The ClinicalTrials.gov registry entry for NCT02633111 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 109-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (360% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which PET/CT is the first listed.
NCT02633111 reports 12 study locations spanning 6 distinct geographic areas - top geographies include New York, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT02633111 about?
NCT02633111 is a clinical study titled "DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas". The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of the study is to see if MRD in blood samples can...
What is the current status of trial NCT02633111?
This trial is currently active not recruiting. The enrollment target is 501 participants. The study started on 2015-10. Estimated completion is 2026-10.
What conditions does trial NCT02633111 study?
This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma, Aggressive.
What interventions are being tested in trial NCT02633111?
The interventions under investigation include: PET/CT (DEVICE), collected at pre-treatment tumor biopsy (OTHER), Peripheral blood tests (OTHER).
Who is sponsoring clinical trial NCT02633111?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02633111 being conducted?
This trial has 12 study locations across Florida, Minnesota, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
RECRUITING · Phase 2
-
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.